ImmunCellAI (26) suggested that glioma patients with a high expression levels of SLC11A1 are more inclined to respond to immunotherapy (79%, 406/509) than patients with low SLC11A1 levels (53%, 273/509) (Figure 6G), and TIDE (27) revealed a similar conclusion (High: 72%, 366/509; Low: 35%, 178/509) (Figure 7C). The gene discussed is SLC11A1; the disease is central nervous system cancer.